Search

Your search keyword '"Higgins, Peter D. R"' showing total 619 results

Search Constraints

Start Over You searched for: Author "Higgins, Peter D. R" Remove constraint Author: "Higgins, Peter D. R"
619 results on '"Higgins, Peter D. R"'

Search Results

4. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study

7. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

9. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

10. Humoral immune response and safety of SARS‐CoV‐2 vaccination in very early onset inflammatory bowel disease

15. Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trial

16. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID

18. Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies

21. Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis

25. Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiota

29. Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis.

36. Dietary Patterns are not Associated with Disease Activity among Patients with Inflammatory Conditions of the Pouch in a Prospective Cohort

39. Profiles of Web-based Portal Users with Inflammatory Bowel Disease

40. Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis

46. Understanding clinician connections to inform efforts to promote high-quality inflammatory bowel disease care

47. sj-docx-1-tag-10.1177_17562848221148254 – Supplemental material for Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease

49. Mapping the adult human esophagus in vivo and in vitro

Catalog

Books, media, physical & digital resources